
Moderna’s Cancer Vaccine Breakthrough Could Usher In A New Era Of Personalised Treatment
A Cancer Vaccine Built For One Patient At A Time Just Passed Phase 3
Moderna has delivered what could become one of the most important validations of mRNA technology since the Covid-19 pandemic.
Its experimental personalised cancer therapy, developed with Merck, has succeeded in a large Phase 3 trial involving patients at high risk of melanoma returning after surgery — pushing Moderna shares dramatically higher and moving a once-futuristic idea much closer to routine cancer medicine.
The treatment, intismeran autogene, is not a conventional vaccine designed to stop healthy people developing…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.